Literature DB >> 20452051

The effect of antipsychotic medication on facial affect recognition in schizophrenia: a review.

Roelie J Hempel1, Judith Anna Dekker, Nico J M van Beveren, Joke H M Tulen, Michiel W Hengeveld.   

Abstract

Patients with schizophrenia suffer from impairments in facial affect recognition and social functioning. Since antipsychotic medication affects different areas in the brain, they may also affect target areas involved in emotional processing mechanisms. In this article, we review the findings of the effect of antipsychotic medication on facial affect recognition in schizophrenia. We searched PubMed for articles in English with the keywords schizophrenia, facial, affect, emotion, antipsychotic and medication, published till January 2008. Eight relevant articles were found describing original studies. No substantial improvements in facial affect recognition were found after treatment with either typical or atypical antipsychotic drugs. Facial affect recognition was not related to neuropsychological functioning, and it was unclear whether improvement of symptom severity was related to performance on the facial affect recognition tasks. It is recommended that future research should focus on measuring social skills and social functioning more directly, and by investigating the effects of additional behavioural treatments on facial affect recognition and social functioning relative to treatment with antipsychotic medication alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452051     DOI: 10.1016/j.psychres.2008.07.025

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR).

Authors:  Wolfgang Wölwer; Nicole Frommann
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

2.  Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.

Authors:  Katarzyna Kucharska-Pietura; Aneta Tylec; Andrzej Czernikiewicz; Ann Mortimer
Journal:  Med Sci Monit       Date:  2012-01

3.  Randomized Clinical Trial with e-MotionalTraining® 1.0 for Social Cognition Rehabilitation in Schizophrenia.

Authors:  Yolanda Maroño Souto; Miriam Vázquez Campo; Francisco Díaz Llenderrozas; Marina Rodríguez Álvarez; Raimundo Mateos; Alejandro García Caballero
Journal:  Front Psychiatry       Date:  2018-02-26       Impact factor: 4.157

4.  Sex Differences in Social Cognition and Association of Social Cognition and Neurocognition in Early Course Schizophrenia.

Authors:  Ryotaro Kubota; Ryo Okubo; Satoru Ikezawa; Makoto Matsui; Leona Adachi; Ayumu Wada; Chinatsu Fujimaki; Yuji Yamada; Koji Saeki; Chika Sumiyoshi; Akiko Kikuchi; Yoshie Omachi; Kazuyoshi Takeda; Ryota Hashimoto; Tomiki Sumiyoshi; Naoki Yoshimura
Journal:  Front Psychol       Date:  2022-04-15

Review 5.  Can antipsychotics improve social cognition in patients with schizophrenia?

Authors:  Katarzyna Kucharska-Pietura; Ann Mortimer
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

6.  Facial affect processing deficits in schizophrenia: a meta-analysis of antipsychotic treatment effects.

Authors:  Anthony S Gabay; Matthew J Kempton; Mitul A Mehta
Journal:  J Psychopharmacol       Date:  2014-12-09       Impact factor: 4.153

7.  Effects of cue modality and emotional category on recognition of nonverbal emotional signals in schizophrenia.

Authors:  Bastian D Vogel; Carolin Brück; Heike Jacob; Mark Eberle; Dirk Wildgruber
Journal:  BMC Psychiatry       Date:  2016-07-07       Impact factor: 3.630

Review 8.  Theory of Mind in Bipolar Disorder, with Comparison to the Impairments Observed in Schizophrenia.

Authors:  Rachel L C Mitchell; Allan H Young
Journal:  Front Psychiatry       Date:  2016-01-18       Impact factor: 4.157

9.  Differences in Facial Emotion Recognition between First Episode Psychosis, Borderline Personality Disorder and Healthy Controls.

Authors:  Ana Catalan; Maider Gonzalez de Artaza; Sonia Bustamante; Pablo Orgaz; Luis Osa; Virxinia Angosto; Cristina Valverde; Amaia Bilbao; Arantza Madrazo; Jim van Os; Miguel Angel Gonzalez-Torres
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.